Medtronic and Alnylam form RNAi drug-device combination deal
This article was originally published in Clinica
Executive Summary
Medtronic has formed a developmental deal with a leading RNAi therapeutics company, Alnylam Pharmaceuticals. The companies will help develop novel drug-device combinations for treating major neurodegenerative diseases such as Huntington's, Alzheimer's and Parkinson's disease.